News Sentiment

TAK sentiment intelligence

Takeda Pharmaceutical Co Ltd ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 59 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 16.56 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

90/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.3% over one week, +4.1% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 90/100 classification
One-week reaction -1.3% Price digesting
Trend fit Trend inactive 4.1% over four weeks
Fair value 16.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 34
Quartr 5
Market source 4
Simply Wall Street 3
www.marketscreener.com 1
Jakarta Globe 1
Investing.com Nigeria 1
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 51
Earnings 4
Balance sheet 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
Stock Titan Direct company coverage

Takeda (TAK) completes long-term incentive share issuance and treasury share disposal

Takeda Pharmaceutical Company Limited announced the completion of its long-term incentive share issuance and treasury share disposal for employees outside Japan. The company issued and disposed of 16,877,109 ordinary shares at 5,050 yen per share, totaling 85,229,400,450 yen. Thi

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 09:40
Source
Stock Titan
BioCentury Direct company coverage

Takeda’s orexin program: The hits, the misses and the payoff

Takeda is nearing the market with oveporexton (TAK-861), an OX2R agonist for narcolepsy type 1, after decades of research into orexin signaling's link to the disease. The company's success is attributed to its unwavering commitment, rapid adaptations to trial designs, and strong

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 00:13
Source
BioCentury
Stock Titan Direct company coverage

Takeda (TAK) director Bruce Broussard receives 3,800 ADS RSUs and 1,319 tax awards

Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard received 3,800 American Depositary Shares (ADS) as restricted stock units (RSUs) and 1,319 Tax Obligation Award units. These equity-based awards, rather than open-market purchases, vest on June 1, 2029, and increase his d

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Takeda (NYSE: TAK) grants 49,558 ADS RSUs to IBU president Platford

Takeda Pharmaceutical (NYSE: TAK) granted 49,558 American Depositary Shares (ADS) as Restricted Stock Units (RSUs) to Giles Richard Platford, President, IBU, as part of his compensation. These RSUs were awarded at no cash cost and will vest in three equal annual installments star

Tone
Neutral 50/100
Event
Balance sheet
Published
06 Jul 2026 22:11
Source
Stock Titan
Stock Titan Direct company coverage

Takeda (NYSE: TAK) director gets RSU grant and manages tax-related share disposition

Takeda Pharmaceutical director Kimberly A. Reed reported new equity awards and tax-related share transactions. She received a grant of 3,800 Ordinary Shares as restricted stock units vesting on June 1, 2029, and 1,319 Tax Obligation Awards. Additionally, 1,152 Tax Obligation Awar

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:11
Source
Stock Titan
Stock Titan Direct company coverage

Takeda (TAK) executive granted 30,094 RSUs, lifting holdings to 87,674 ADS

Takeda Pharmaceutical executive Shannon Elaine Mary received a grant of 30,094 Restricted Stock Units (RSUs), increasing her total holdings to 87,674 American Depositary Shares (ADS). These RSUs, which were awarded as part of compensation at a $0.00 stated price, will vest in thr

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:11
Source
Stock Titan
Stock Titan Direct company coverage

Takeda (TAK) chief communications officer receives 18,808 RSU share award

Takeda Pharmaceutical's Chief Communications & Government Officer, Jennifer Marie Smoter, was granted an equity award of 18,808 American Depositary Shares in the form of restricted stock units (RSUs). These RSUs will vest in three equal annual installments starting on July 1, 202

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:11
Source
Stock Titan
Stock Titan Direct company coverage

Takeda (NYSE: TAK) grants 37,616 ADS RSUs to tech chief Ricci

Takeda Pharmaceutical (NYSE: TAK) has granted its Chief Data & Technology Officer, Gabriele Ricci, 37,616 American Depositary Shares (ADS) in the form of restricted stock units (RSUs). These RSUs were awarded at no cost and will vest in three equal annual installments beginning J

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:11
Source
Stock Titan
Stock Titan Direct company coverage

Takeda (NYSE: TAK) unit president gets RSU grant and tax awards

Asuka Miyabashira, President of Takeda Pharmaceutical's Japan Pharma Business Unit, received a grant of 1,500 Ordinary Shares and several Tax Obligation Awards. This transaction increased her direct ownership to 4,500 shares. Additionally, 1,022 vested Tax Obligation Awards were

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 22:11
Source
Stock Titan
Stock Titan Direct company coverage

Takeda (NYSE: TAK) director Paulus Stoffels receives share and tax-linked awards

Takeda director Paulus Stoffels reported receiving equity compensation, including 3,800 Ordinary Shares and 1,307 Tax Obligation Awards. These awards are part of his director compensation, with the shares going into his direct holdings and the tax awards vesting as cash on June 1

Tone
Neutral 50/100
Event
Balance sheet
Published
06 Jul 2026 21:11
Source
Stock Titan
Stock Titan Direct company coverage

Director Paulus Stoffels files initial Form 3 for Takeda (NYSE: TAK)

Takeda director Paulus Stoffels has filed an initial Form 3 with the SEC, indicating his insider status as a director of the company. This filing is a baseline disclosure and reports no transactions or derivative positions in Takeda's securities. It serves to establish his benefi

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 15:42
Source
Stock Titan
Simply Wall Street Direct company coverage

Takeda Pharmaceutical (TSE:4502) Is Up 5.3% After New Insilico AI Drug Discovery Deal - Has The Bull Case Changed?

Takeda Pharmaceutical's stock rose 5.3% following its collaboration with Insilico Medicine to use its Pharma.AI platform for drug discovery, a deal potentially worth up to US$600 million plus royalties. This partnership, alongside the new CEO Julie Kim, could significantly influe

Tone
Positive 70/100
Event
Deals and strategy
Published
06 Jul 2026 03:40
Source
Simply Wall Street
TradingView Direct company coverage

ETFs Investing in Takeda Pharmaceutical Co. Ltd. Sponsored ADR Stocks

This article lists various ETFs that include Takeda Pharmaceutical Co. Ltd. Sponsored ADR stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of Takeda stock, issuer, management style, expense ratio, assets under managem

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 03:40
Source
TradingView
Simply Wall Street Direct company coverage

Takeda (TSE:4502) Stock Still Looks Slightly Undervalued Overall

Takeda Pharmaceutical (TSE:4502) stock has shown strong returns over the past five years but presents a nuanced valuation picture, screening as undervalued in 4 of 6 checks according to Simply Wall St's framework. The company's P/S ratio of 1.9x is slightly above the industry ave

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 08:10
Source
Simply Wall Street